DIOSynVax任命Ron Moss医学博士为首席执行官-动脉网

DIOSynVax Appoints Ron Moss, MD, as CEO

CISION 等信源发布 2024-10-01 21:07



可切换为仅中文







CAMBRIDGE, England, Oct. 1, 2024 /PRNewswire/ -- DIOSynVax, a pioneering clinical-stage biotechnology company specializing in revolutionary broadly protective vaccines, is thrilled to announce the appointment of Ron Moss MD, as its new Chief Executive Officer (CEO), reporting to its board of directors, effective September 1, 2024.

英国剑桥，2024年10月1日/PRNewswire/--DIOSynVax是一家开创性的临床阶段生物技术公司，专门从事革命性的广泛保护性疫苗，很高兴宣布任命Ron Moss MD为其新任首席执行官（CEO），并向董事会报告，自2024年9月1日起生效。

Dr. Moss, who brings over 30 years of distinguished experience in biopharma, will be based in the USA. He succeeds the company's founder, Professor Jonathan Heeney of Cambridge University, who will transition to the role of Chief Scientific Officer. DIOSynVax's unique approach develops vaccines to a variety of infectious disease targets to prevent future pandemics and will make the need for frequent vaccinations obsolete..

莫斯博士在生物制药领域拥有30多年的杰出经验，将常驻美国。他将接替公司创始人、剑桥大学乔纳森·希尼教授（JonathanHeeney）出任首席科学官。DIOSynVax独特的方法开发了针对各种传染病目标的疫苗，以预防未来的大流行，并将淘汰频繁接种疫苗的需求。。

Dr. Moss's extensive background includes senior executive roles across the biopharma industry, where he has led efforts in multiple Biologics License Applications (BLAs), New Drug Applications (NDAs) as well as funding rounds from both public and private equity. His deep expertise in Clinical Vaccine Development will be instrumental as DIOSynVax advances through clinical Proof of Concept (PoC) of its groundbreaking technology that leverages computational biology to design next-generation vaccines with broad protective capabilities..

莫斯博士的广泛背景包括生物制药行业的高级管理人员，他曾领导多项生物制剂许可证申请（BLA），新药申请（NDA）以及公共和私人股本的融资回合。随着DIOSynVax通过其开创性技术的临床概念验证（PoC）取得进展，他在临床疫苗开发方面的深厚专业知识将发挥重要作用，该技术利用计算生物学来设计具有广泛保护能力的下一代疫苗。。

'Ron's impressive track record in executive leadership and vaccine development positions him perfectly to drive DIOSynVax's mission forward,' said Professor Heeney. 'His strategic vision and extensive experience will enhance the value of our disruptive technology, which aims to create vaccines that are innovative and very importantly broadly protective against both current and emerging pandemics.

希尼教授说：“罗恩在高管领导和疫苗开发方面的出色业绩，使他能够完美地推动迪奥辛瓦克斯的使命向前发展。”他的战略远见和丰富的经验将提高我们破坏性技术的价值，该技术旨在创造创新的疫苗，并且非常重要的是可以广泛预防当前和新出现的流行病。

We are confident given Ron's proven track record in successfully completing clinical trials that DIOSynVax is strategically positioned to make significant strides in advancing our vaccines through to clinical application.'.

鉴于罗恩在成功完成临床试验方面的良好记录，我们有信心DIOSynVax处于战略地位，可以在将我们的疫苗推进临床应用方面取得重大进展。”。

Dr. Moss stated, 'I am excited to lead the DIOSynVax team through the next stages of clinical approval and application. Our technology has the potential to revolutionize vaccine development by providing a new generation of vaccines for broad protection against the growing number of severe viral diseases. DIOSynVax's technology allows us to stay ahead of future pandemics using its unique computational and preclinical pipeline to select vaccines to provide protection against disease causes, including current threats such as the large number of bird flu strains that imminently threaten human kind.

莫斯博士表示，“我很高兴能够领导DIOSynVax团队完成下一阶段的临床批准和应用。我们的技术有可能通过提供新一代疫苗来广泛预防越来越多的严重病毒性疾病，从而彻底改变疫苗开发。DIOSynVax的技术使我们能够利用其独特的计算和临床前流程来选择疫苗，以提供针对疾病原因的保护，从而领先于未来的大流行，包括目前威胁人类的大量禽流感病毒株。

Having vaccines in our arsenal that protect against future threats is our reachable goal. Our approach will also make the need for yearly vaccinations no longer necessary.'.

。我们的方法也将不再需要每年接种疫苗。”。

The Company will be presenting its new pan-bird flu vaccine data at the upcoming Options XII conference for Advancements in Influenza Control in Brisbane Australia on October 2, 2024. Details to follow.

该公司将于2024年10月2日在澳大利亚布里斯班举行的流感控制进展选项十二会议上展示其新的泛禽流感疫苗数据。要遵循的详细信息。

What if we had vaccines that didn't constantly need updates? Check out our new study demonstrating the breadth of protection our new vaccine technology achieves over time.

如果我们有不需要不断更新的疫苗呢？看看我们的新研究，它展示了我们的新疫苗技术随着时间的推移所取得的广泛保护。

https://www.nature.com/articles/s41551-023-01094-2

About H5N1

关于H5N1

Bird-flu or H5N1 infections is widespread in birds and cattle. A number of document infections have been found in humans some with and without contact to infected animals (https://www.cdc.gov/bird-flu/situation-summary/index.html).

禽流感或H5N1感染在禽类和牲畜中普遍存在。在人类中发现了许多文件感染，其中一些与受感染的动物有或没有接触(https://www.cdc.gov/bird-flu/situation-summary/index.html)。

Most public health experts agree that bird-flu does pose a risk to humans should additional changes in the virus occur The US is entering a riskier season for spread of H5N1 bird flu. Here's why experts are worried (msn.com).

大多数公共卫生专家同意，如果病毒发生其他变化，禽流感确实会对人类构成风险。美国正进入H5N1禽流感传播的风险更高的季节。以下是专家们担心的原因（msn.com）。

About DIOSynVax

关于DIOSynVax

Co-founded by Professor Jonathan Heeney of Cambridge University, UK, Professor Ralf Wagner of University of Regensburg, Germany, and Professor Simon Frost Principal Data Scientist at Microsoft Research, Seattle, USA. DIOSynVax is a clinical-stage biotechnology company dedicated to developing universal vaccines through advanced computational biology technologies.

由英国剑桥大学乔纳森·希尼教授、德国雷根斯堡大学拉尔夫·瓦格纳教授和美国西雅图微软研究院首席数据科学家西蒙·弗罗斯特教授共同创立。DIOSynVax是一家临床阶段生物技术公司，致力于通过先进的计算生物学技术开发通用疫苗。

Their mission is to create innovative solutions that provide broad protection against a wide range of infectious diseases, including emerging pandemics..

他们的使命是创造创新的解决方案，为包括新出现的流行病在内的各种传染病提供广泛的保护。。

For media inquiries or more information, please contact: media@diosvax.com.

有关媒体查询或更多信息，请联系：media@diosvax.com.

SOURCE DIOSynVax

源地闪合成

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

想在PRNEWSWIRE上发布贵公司的新闻。COM？

440k+

44万+

Newsrooms &

新闻编辑室&

Influencers